Skip to the guide
EXACT 41

Melanocortin signalling / EDUCATIONAL GUIDE

PT-141

PT-141 10 mg box packaging mockup
Packaging mockup
10 mg€29.90

Research aims, observed effects
and the limits of the evidence.

Specific approved medicine existsSources checked 6 September 2026

THE IDEA IN EVERYDAY TERMS

Sexual desire in a defined patient group

PT-141 is bremelanotide, which activates melanocortin receptors. Its approved medicine, Vyleesi, treats a specific form of low sexual desire that causes distress in premenopausal women. Researchers measured desire and the distress associated with it; these are more specific outcomes than a general promise of improved sexual performance.

Read the background ↗

Human trials; specific medicine approved

What has actually been shown?

The trials found improvements in desire scores and related distress compared with placebo. The precise mechanism behind the clinical effect remains incompletely understood. The approval does not cover general performance enhancement or use in men. Important risks include nausea and temporary blood-pressure increases; the label excludes people with uncontrolled hypertension or known cardiovascular disease.

Read the evidence ↗

01 / OVERVIEW

What is PT-141?

PT-141 is also known as bremelanotide, a melanocortin-receptor agonist. Vyleesi is its approved medicinal formulation. [1]

02 / RESEARCH AIMS

Why it is studied.

Vyleesi is indicated for acquired, generalized hypoactive sexual desire disorder in premenopausal women meeting the label criteria. It is not a general sexual-performance enhancer. [1]

03 / RESEARCH MAP

Following the research question.

Bremelanotide activates melanocortin receptors. The precise mechanism responsible for the labelled clinical effect is not fully known. [1]

PT-141 research map: Melanocortin receptors; Mechanism partly unresolved; Defined HSDD populationRESEARCH MAP / PT-14101Melanocortin receptors02Mechanism partly unresolved03Defined HSDD population
Conceptual research map, not a molecular structure or a proven chain of clinical effects. [1]

04 / OBSERVED EFFECTS

What the evidence shows.

Clinical trials evaluated desire and related distress in a defined patient group. Those findings should not be generalized to men, other diagnoses or unverified preparations. [1]

Study context

Human clinical trials

Key distinction

Narrow approved indication

Uncertainty

No general performance claim

A selected-source overview, not a systematic review. Research findings are not verified effects of an independently supplied sample.

05 / SAFETY AND LIMITATIONS

Risks belong beside the findings.

Important risks include transient blood-pressure increases, nausea and focal hyperpigmentation. The label contraindicates use with uncontrolled hypertension or known cardiovascular disease. [1]

Approval and clinical findings apply to the approved medicine and population, not a vial identified only as PT-141.

06 / REFERENCES

Go to the source.

  1. DailyMed — Vyleesi prescribing information ↗

    Official label: clinical studies, indication and safety.